Back to top
more

Nabriva Therapeutics AG (NBRV)

(Delayed Data from NSDQ)

$2.16 USD

2.16
1,618,904

+0.01 (0.47%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.16 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Paratek's (PRTK) NDAs for Omadacycline Get Priority Review

by Zacks Equity Research

Paratek Pharmaceuticals (PRTK) is seeking approval for its antibiotic candidate, omadacycline, for the treatment of CABP and ABSSSI in the United States.

    Nabriva's Lefamulin Positive in Pivotal Study, Stock Surges

    by Zacks Equity Research

    Nabriva Therapeutics' (NBRV) lefamulin shows non-inferiority to Avelox in a phase III study on community-acquired bacterial pneumonia patients.

      Madeleine Johnson headshot

      Here's Why Nabriva Therapeutics (NBRV) Stock is Surging Today

      by Madeleine Johnson

      On Monday, shares of biopharmaceutical company Nabriva Therapeutics (NBRV) are surging, up over about 32% in morning trading--the stock skyrocketed 102% in premarket trade--after it announced positive late-stage trial results from its pneumonia treatment, lefamulin.

        Nabriva Therapeutics (NBRV) Catches Eye: Stock Gains 9.8%

        by Zacks Equity Research

        Nabriva Therapeutics AG (NBRV) moved big last session, as its shares rose almost 10% on the day.